Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an update.
Pharmaron Beijing Co., Ltd. has entered into a placing agreement with Goldman Sachs (Asia) L.L.C. and The Hongkong and Shanghai Banking Corporation Limited to issue 58,440,762 new H shares at HK$22.82 per share under its existing general issuance mandate. The new shares represent about 19.86% of its existing H-share capital and 3.30% of total issued shares, and will be allocated to at least six independent professional, institutional and other investors, with listing approval to be sought from the Hong Kong Stock Exchange; while the transaction is not subject to further shareholder approval, completion remains conditional and may not proceed, prompting the company to urge shareholders and investors to exercise caution.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based life sciences and pharmaceutical services company listed in Hong Kong, primarily engaged in providing contract research, development and manufacturing services to global pharmaceutical and biotech clients. The group focuses on supporting drug discovery and development across the value chain, leveraging its scientific platforms and international capital markets access to fund expansion and operations.
Average Trading Volume: 5,133,709
Technical Sentiment Signal: Buy
Current Market Cap: HK$58.28B
See more data about 3759 stock on TipRanks’ Stock Analysis page.